FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367303934> ?p ?o ?g. }

• W4367303934 abstract "<h3>Objective:</h3> This study aimed to characterize the relationship between lacosamide pharmacokinetics and renal function in older adults with epilepsy. <h3>Background:</h3> Lacosamide is an anti-seizure medication (ASM) indicated for focal-onset seizures which is primarily excreted through the renal route. Changes in clearance with increased age could lead to pharmacokinetic changes in medications that are eliminated via the kidney; therefore, older adults, being more sensitive to these changes may need lower doses than younger adults. <h3>Design/Methods:</h3> Data on patients diagnosed with epilepsy according to ICD10 codes and having at least one steady-state lacosamide concentration measurement between January 2015 and July 2020 met inclusion. A linear mixed model was developed to characterize differences in lacosamide dose normalized concentrations (DNCs = blood concentration/total daily dose) with respect to creatinine clearance (CLCR). CLCR was calculated using the Cockcroft-Gault equation as indicated for lacosamide dosing (package insert), thus incorporating the effect of patient age and sex. The model was controlled for covariates including ethnicity, route of administration (oral/intravenous), aspartate aminotransferase concentration, alanine aminotransferase concentration, regime (monotherapy/polytherapy), presence of CYP450 inducers & inhibitors, and critically ill status as signified by prescription. Model significance was set to α≤0.05 (R software (version 4.1.2)). <h3>Results:</h3> 2291 lacosamide DNCs from 676 patients were included. The median[range] dose and DNC were 300 mg [50–1000 mg] and 23(ug/L)/mg [1–480(ug/L)/mg], respectively. For a given subject the mean DNC of lacosamide decreased by 6% (95% confidence interval: 3.5–8.9%, p<0.01) per unit increase in the CLCR. Route of administration (p=0.01) and presence of a CYP450 inducer (p<0.01) showed a statistically significant effect on DNCs. <h3>Conclusions:</h3> Creatinine clearance was a significant predictor of lacosamide DNCs in older patients with epilepsy. Thus, as CLCR changes are more pronounced as one ages, modification in dosing regimens may be required to maintain lacosamide concentrations in the tolerable and effective range. <b>Disclosure:</b> Miss Avachat has nothing to disclose. The institution of Dr. Reeder has received research support from American Epilepsy Society . Mr. Long has received personal compensation for serving as an employee of PharmaVelox. Dr. Leppik has nothing to disclose. The institution of Dr. Patel has received research support from Ucb. The institution of Dr. Birnbaum has received research support from National Institutes of Health. Dr. Birnbaum has received intellectual property interests from a discovery or technology relating to health care." @default.
• W4367303934 created "2023-04-29" @default.
• W4367303934 creator A5000188838 @default.
• W4367303934 creator A5003145324 @default.
• W4367303934 creator A5008904502 @default.
• W4367303934 creator A5021645428 @default.
• W4367303934 creator A5038936604 @default.
• W4367303934 creator A5063550822 @default.
• W4367303934 date "2023-04-25" @default.
• W4367303934 modified "2023-10-01" @default.
• W4367303934 title "Characterization of lacosamide pharmacokinetics in older adults with epilepsy (P4-1.007)" @default.
• W4367303934 doi "https://doi.org/10.1212/wnl.0000000000203026" @default.
• W4367303934 hasPublicationYear "2023" @default.
• W4367303934 type Work @default.
• W4367303934 citedByCount "0" @default.
• W4367303934 crossrefType "proceedings-article" @default.
• W4367303934 hasAuthorship W4367303934A5000188838 @default.
• W4367303934 hasAuthorship W4367303934A5003145324 @default.
• W4367303934 hasAuthorship W4367303934A5008904502 @default.
• W4367303934 hasAuthorship W4367303934A5021645428 @default.
• W4367303934 hasAuthorship W4367303934A5038936604 @default.
• W4367303934 hasAuthorship W4367303934A5063550822 @default.
• W4367303934 hasConcept C112705442 @default.
• W4367303934 hasConcept C118552586 @default.
• W4367303934 hasConcept C126322002 @default.
• W4367303934 hasConcept C159641895 @default.
• W4367303934 hasConcept C2426938 @default.
• W4367303934 hasConcept C2777288759 @default.
• W4367303934 hasConcept C2778139780 @default.
• W4367303934 hasConcept C2778186239 @default.
• W4367303934 hasConcept C71924100 @default.
• W4367303934 hasConcept C98274493 @default.
• W4367303934 hasConceptScore W4367303934C112705442 @default.
• W4367303934 hasConceptScore W4367303934C118552586 @default.
• W4367303934 hasConceptScore W4367303934C126322002 @default.
• W4367303934 hasConceptScore W4367303934C159641895 @default.
• W4367303934 hasConceptScore W4367303934C2426938 @default.
• W4367303934 hasConceptScore W4367303934C2777288759 @default.
• W4367303934 hasConceptScore W4367303934C2778139780 @default.
• W4367303934 hasConceptScore W4367303934C2778186239 @default.
• W4367303934 hasConceptScore W4367303934C71924100 @default.
• W4367303934 hasConceptScore W4367303934C98274493 @default.
• W4367303934 hasLocation W43673039341 @default.
• W4367303934 hasOpenAccess W4367303934 @default.
• W4367303934 hasPrimaryLocation W43673039341 @default.
• W4367303934 hasRelatedWork W2000782600 @default.
• W4367303934 hasRelatedWork W2004325424 @default.
• W4367303934 hasRelatedWork W2009820498 @default.
• W4367303934 hasRelatedWork W2021831895 @default.
• W4367303934 hasRelatedWork W2077316270 @default.
• W4367303934 hasRelatedWork W2080969318 @default.
• W4367303934 hasRelatedWork W2159599047 @default.
• W4367303934 hasRelatedWork W2207503964 @default.
• W4367303934 hasRelatedWork W2793520024 @default.
• W4367303934 hasRelatedWork W2794476093 @default.
• W4367303934 isParatext "false" @default.
• W4367303934 isRetracted "false" @default.
• W4367303934 workType "article" @default.